Search research articles
Contact Us
Filters
Showing results (41-50 of 148) with videos related to
Page
of 15
Sort By:
Anticancer Research
|
November 2, 2010
Impact of tumor biology, particularly triple-negative status, on response to pre-operative sequential, dose-dense epirubicin, cyclophosphamide followed by docetaxel in breast cancer
M Warm, R Kates, Em Grosse-Onnebrink, et al.
Breast Cancer Research and Treatment
|
July 29, 1999
Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse
N Harbeck, C Thomssen, U Berger, et al.
ESMO Open
|
November 28, 2025
Long-term outcome data for patients with hormone receptor-positive early breast cancer participating in the WSG PlanB trial after preselection by gene expression analysis: 10-year survival results from the WSG PlanB registry
U Nitz, M Graeser, O Gluz, et al.
ESMO Open
|
November 30, 2025
Promoting equitable access to financial services to end financial discrimination against cancer survivors in Europe: scientific and ethical reasons
F André, D Soldato, I Vaz-Luis, et al.
International Journal of Oncology
|
March 24, 1999
HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer
N Harbeck, J S Ross, S Yurdseven, et al.
Advances in Clinical Chemistry
|
April 24, 2008
uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial
K Annecke, M Schmitt, U Euler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 14, 2001
Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy
N Harbeck, U Alt, U Berger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 7, 2010
Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer
J Dorn, N Harbeck, R Kates, et al.
Thrombosis and Haemostasis
|
July 1, 1997
Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy
M Schmitt, N Harbeck, C Thomssen, et al.
Archives of Gynecology and Obstetrics
|
March 28, 2026
Tumor biology, treatment patterns, and recurrence in breast cancer patients aged 70-79 vs ≥ 80 years: a large-scale registry analysis
F Ganster, S Schrodi, M Braun, et al.
Page
of 15
Search research articles
Search
Showing results (41-50 of 148) with videos related to
Sort By:
Page
of 15
Anticancer Research
|
November 2, 2010
Impact of tumor biology, particularly triple-negative status, on response to pre-operative sequential, dose-dense epirubicin, cyclophosphamide followed by docetaxel in breast cancer
M Warm, R Kates, Em Grosse-Onnebrink, et al.
Breast Cancer Research and Treatment
|
July 29, 1999
Invasion marker PAI-1 remains a strong prognostic factor after long-term follow-up both for primary breast cancer and following first relapse
N Harbeck, C Thomssen, U Berger, et al.
ESMO Open
|
November 28, 2025
Long-term outcome data for patients with hormone receptor-positive early breast cancer participating in the WSG PlanB trial after preselection by gene expression analysis: 10-year survival results from the WSG PlanB registry
U Nitz, M Graeser, O Gluz, et al.
ESMO Open
|
November 30, 2025
Promoting equitable access to financial services to end financial discrimination against cancer survivors in Europe: scientific and ethical reasons
F André, D Soldato, I Vaz-Luis, et al.
International Journal of Oncology
|
March 24, 1999
HER-2/neu gene amplification by fluorescence in situ hybridization allows risk-group assessment in node-negative breast cancer
N Harbeck, J S Ross, S Yurdseven, et al.
Advances in Clinical Chemistry
|
April 24, 2008
uPA and PAI-1 in breast cancer: review of their clinical utility and current validation in the prospective NNBC-3 trial
K Annecke, M Schmitt, U Euler, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research
|
September 14, 2001
Prognostic impact of proteolytic factors (urokinase-type plasminogen activator, plasminogen activator inhibitor 1, and cathepsins B, D, and L) in primary breast cancer reflects effects of adjuvant systemic therapy
N Harbeck, U Alt, U Berger, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology
|
October 7, 2010
Impact of expression differences of kallikrein-related peptidases and of uPA and PAI-1 between primary tumor and omentum metastasis in advanced ovarian cancer
J Dorn, N Harbeck, R Kates, et al.
Thrombosis and Haemostasis
|
July 1, 1997
Clinical impact of the plasminogen activation system in tumor invasion and metastasis: prognostic relevance and target for therapy
M Schmitt, N Harbeck, C Thomssen, et al.
Archives of Gynecology and Obstetrics
|
March 28, 2026
Tumor biology, treatment patterns, and recurrence in breast cancer patients aged 70-79 vs ≥ 80 years: a large-scale registry analysis
F Ganster, S Schrodi, M Braun, et al.
Page
of 15